Are there age-and sex-specific differences in the use of evidence-based medication in heart failure patients?

Project number: 
Approval date: 
Friday, December 4, 2015
Principal Investigator: 
University of British Columbia (UBC)
Funding Agency: 
Not Available
Datasets requested: 
Deaths (BC Vital Statistics Agency)
Medical Services Plan (BC Ministry of Health)
Consolidation file (BC Ministry of Health)
Hospital Separations (BC Ministry of Health)
Research objective: 

Specific aims:
To determine the age-specific patterns of use of guideline-recommended medical therapies in the management of heart failure (HF) in a Canadian population-based cohort.

Primary aim:
To determine the rates of use of guideline-recommended medications as defined by having an active prescription for beta blocker (BB), angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB), and mineralocorticoid receptor antagonist (MRA) when indicated at 30-days, 90-days, 180-days and 1-year post incident heart failure admission in those who are older compared to younger than 65 years of age in a Canadian population-based cohort.

Secondary aims:
1. To determine if there are any age-specific differences in the young vs. old HF patients with respect to:
-the average and total dose of BB, ACEi/ARB, and MRA at 30-d, 90-d, 180-d and 1-year post incident heart failure hospitalization
-the proportion of patients on low-dose vs. high-dose vs. not on med with respect to BB, ACEi/ARB MRA at 1-year post incident HF hospitalization
2. To determine the relationship between being on BB, ACEi/ARB and/or MRA and 1-year rehospitalisation for HF or cardiovascular (CV)-related as well as 1-year mortality in those who are young vs. old

-The rate of use of BB, ACEi/ARB and MRA will be higher in the younger compared to the older patients
-The average and cumulative dose of BB, ACEi/ARB and MRA will be higher in the younger compared to older patients
-Use of evidence based therapies (ie. being on BB, ACEi/ARB and MRA vs. not) will result in decreased rehospitalization rates and reduced mortality in both the young as well as old HF patients.

Page last revised: September 2, 2019